|
WO02079517A1
|
|
Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
|
|
CA2434671A1
|
|
Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor
|
|
IL154358D0
|
|
Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
|
|
US6492428B1
|
|
Compounds having MIF antagonist activity
|
|
WO0103644A2
|
|
Pyrazolopyrimidinone derivatives conjugated to thiophene moieties or benzo [fused] 5-membered heterocycles for erectile dysfunction
|
|
AU4271700A
|
|
Treatment of HIV-infection by interfering with host cell cyclophilin receptor activity
|
|
AU4252700A
|
|
Methods for measurement and treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
|
|
US6538131B1
|
|
Synthetic process for highly functionalized carbocyclic polyols and substituted sugar analogs
|
|
AU4013199A
|
|
Tobacco combustion product filter
|
|
US6110968A
|
|
Methods for treatment predicated on the presence of advanced glycosylation endproducts in tobacco and its combustion byproducts
|
|
AU8657398A
|
|
Immunotherapeutic anti-cancer pharmaceutical compositions
|
|
US6025401A
|
|
Method and agents for inhibiting protein aging
|
|
WO9820868A1
|
|
Guanylhydrazones useful for treating diseases associated with t cell activation
|
|
US6413939B1
|
|
Inducible phosphofructokinase and the Warburg effect
|
|
US2002022234A1
|
|
Immunological advanced glycation endproduct crosslink
|
|
US6011005A
|
|
Prevention of pregnancy miscarriages
|
|
AU3751397A
|
|
Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
|
|
US5808068A
|
|
HIV nuclear localization inhibitors
|
|
US6019979A
|
|
Anti-viral treatment with pertussis toxin B oligomer
|
|
US5849793A
|
|
HIV matrix protein tyrosine position 29 pocket binders
|
